Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
David C. D. Hope, Matthew L. Vincent, Tricia Tan
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 104
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
Tina Zimmermann, Leo Thomas, Tamara Baader-Pagler, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101633-101633
Open Access | Times Cited: 79
Obesity and diabetes
Chrysoula Boutari, Antea DeMarsilis, Christos S. Mantzoros
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110773-110773
Closed Access | Times Cited: 57
Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) – Proceedings from the SOGLI consortium meeting in Rome November 2022
Gianluca Gortan Cappellari, Christelle Guillet, Eleonora Poggiogalle, et al.
Clinical Nutrition (2023) Vol. 42, Iss. 5, pp. 687-699
Open Access | Times Cited: 52
Glucagon‐like peptide agonists: A prospective review
Zamara Mariam, Sarfaraz K. Niazi
Endocrinology Diabetes & Metabolism (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 49
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 33
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 30
The past, present, and future physiology and pharmacology of glucagon
Megan E. Capozzi, David A. D’Alessio, Jonathan E. Campbell
Cell Metabolism (2022) Vol. 34, Iss. 11, pp. 1654-1674
Open Access | Times Cited: 54
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3094-3094
Open Access | Times Cited: 36
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Linong Ji, Hongwei� Jiang, Zhi-Feng Cheng, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, et al.
Molecular Metabolism (2023) Vol. 78, pp. 101801-101801
Open Access | Times Cited: 24
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
The importance of estradiol for body weight regulation in women
Pilar Vigil, Jaime Meléndez, Grace Petkovic, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 36
GLP-1 receptor agonist as a modulator of innate immunity
Jun Chen, Aihua Mei, Yingying Wei, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
360-Degree Perspectives on Obesity
Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1119-1119
Open Access | Times Cited: 20
MASLD treatment—a shift in the paradigm is imminent
Mariana Verdelho Machado
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 18
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 6
Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
Lotte Simonsen, Jesper Lau, Thomas Kruse, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0264974-e0264974
Open Access | Times Cited: 24
The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
Leo Thomas, Eric Martel, Wolfgang Rist, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2368-2378
Open Access | Times Cited: 5
A roadmap for clinical trials in MASH-related compensated cirrhosis
Juan M. Pericàs, Quentin M. Anstee, Salvador Augustín, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 11, pp. 809-823
Closed Access | Times Cited: 5
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Wael R. Sidrak, Sanjay Kalra, Atul Kalhan
Indian Journal of Endocrinology and Metabolism (2024) Vol. 28, Iss. 5, pp. 445-460
Open Access | Times Cited: 5
Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
David C. D. Hope, Charlotte E. Hinds, Tatiana Lopes, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100810-100810
Open Access | Times Cited: 22
Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities
Mohammad Amin Manavi
Neuropeptides (2022) Vol. 94, pp. 102250-102250
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top